Organization (Industry)
TELEFLEX INC
ClinicalTrials.gov lists TELEFLEX INC as lead sponsor of 29 trials, counting the companies grouped under it. TELEFLEX INC itself has 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
Logo Teleflex Incorporated, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers TELEFLEX INC and 6 companies grouped under it: 29 lead-sponsored trials (11 its own, 18 in the grouped companies) and 7 legal-entity registrations (7 its own, 0 in the grouped companies).
Companies grouped under this page (6)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Vascular Solutions LLC | 7 | 0 |
| Essential Medical, Inc. | 6 | 0 |
| Palette Life Sciences, Inc. | 2 | 0 |
| Standard Bariatrics | 2 | 0 |
| Z-Medica | 1 | 0 |
Showing 5 of 6 member companies.
Disease areas (27)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 3 |
| Cicatrix | 2 |
| Coronary Artery Disease | 2 |
| Coronary Disease | 2 |
| Fibrosis | 2 |
Showing 5 of 27 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 2 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Freeze Dried Plasma (FDP) | 2 |
| Conventional Plasma | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 3 hit target (n=3) | 0 of 2 on time (n=2) |
Journals published in (27)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Anesthesia and analgesia | 5 |
| Regional anesthesia and pain medicine | 5 |
| American journal of infection control | 4 |
| Anaesthesia | 4 |
| British journal of anaesthesia | 4 |
Showing 5 of 27 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 303 | 0 | 2017-01-10 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 1,992,713,000 | -905,640,000 | 144,781,000 |
| 2024 | 1,699,546,000 | 69,675,000 | 109,021,000 |
| 2023 | 1,712,441,000 | 356,328,000 | 113,627,000 |
| 2022 | 2,791,041,000 | 363,139,000 | 153,819,000 |
| 2021 | 2,809,563,000 | 485,374,000 | 130,841,000 |
| 2020 | 2,537,156,000 | 335,324,000 | 119,747,000 |
| 2019 | 2,595,362,000 | 461,466,000 | 113,857,000 |
| 2018 | 2,448,383,000 | 200,802,000 | 106,208,000 |
| 2017 | 2,146,303,000 | 152,530,000 | 84,770,000 |
| 2016 | 1,868,027,000 | 237,377,000 | 58,579,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (20)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-08-03 | Other financing | not disclosed | Sec extracted |
| 2026-06-15 | Debt financing | 500,000,000 | Sec extracted |
| 2026-06-01 | Debt financing | not disclosed | Sec extracted |
| 2026-06-01 | Debt financing | not disclosed | Sec extracted |
| 2026-05-26 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 20 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 15 |
FDA recalls (151)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Brand Name: Pilling Wecksorb Product Name: Pilling Wecksorb Neurosponges (Cotton) Pilling¿ Wecksorb Neurosponge Strips (Cotton) Model/Catalog Number: 200100 200101 200102 200103 200104 200105 200106 200108 200110 200112 200120 200121 200123 200131 Software Version: N/A Product Description: Wecksorb Neurosponges are made of an absorbent cotton material. Certain Neurosponge varieties are available with an x-ray detectable thread to assist with location within the surgical site. Some Neurosponges (patties) have a string for accountability during the post-surgical verification process. Wecksorb Neurosponges are for use in the protection of tissue during surgical procedures; tissues include the brain and other central nervous system tissues. Neuro sponges are used during cranial and spine surgery to moisten the dura or to cushion against bone edges. They are also used to protect brain tissue under the dura or elsewhere during incision. Component: N/A | Class II | 2026-05-07 |
| Slick Set Cuffed Endotracheal Tube and Stylet Set, oral/nasal, REF 170050 | Class I | 2023-05-25 |
| Slick Set Cuffed Endotracheal Tube and Stylet Set, oral/nasal, REF 170055 | Class I | 2023-05-25 |
| Slick Set Cuffed Endotracheal Tube and Stylet Set, oral/nasal, REF 170060 | Class I | 2023-05-25 |
| Slick Set Cuffed Endotracheal Tube and Stylet Set, oral/nasal, REF 170065 | Class I | 2023-05-25 |
Showing 5 of 151 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 4 | 2022-04-20 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Teleflex LLC (NADC) | Olive Branch, US | FDA | |
| Teleflex LLC | Brooklyn Park, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (538)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-03 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-15 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-01 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 538 events.
Biomarker capability evidence (30)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FOLH1 | Trial collaborator | Named in trial inclusion criteria |
| KLK3 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial exclusion criteria |
| CYP2C9 | Trial sponsor | Named in trial exclusion criteria |
| DLD | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 30 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, fda warning letters, fda untitled letters, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.